0000899243-22-014403.txt : 20220411 0000899243-22-014403.hdr.sgml : 20220411 20220411060517 ACCESSION NUMBER: 0000899243-22-014403 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220404 FILED AS OF DATE: 20220411 DATE AS OF CHANGE: 20220411 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: John Johnny CENTRAL INDEX KEY: 0001922221 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 22818414 MAIL ADDRESS: STREET 1: C/O DELCATH SYSTEMS, INC. STREET 2: 1633 BROADWAY, SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 489-2100 MAIL ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-04-04 0 0000872912 DELCATH SYSTEMS, INC. DCTH 0001922221 John Johnny C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C NEW YORK NY 10019 0 1 0 0 See Remarks Stock Option (right to buy) 11.67 2030-10-01 Common Stock 75000 D Stock Option (right to buy) 10.16 2031-08-05 Common Stock 50000 D The option vests and becomes exercisable at the rate of one-thirty-sixth (1/36th) per month on the first day of each month over a 36-month period that commenced on October 1, 2020, subject to the reporting person's continued employment with the issuer on each respective vesting date. The option vested and became exercisable with respect to four-thirty-sixths (4/36ths) of the option shares and the remaining option shares vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month on the first day of each month over a 32-month period that commenced on September 1, 2021, subject to the reporting person's continued employment with the issuer on each respective vesting date. Senior Vice President Clinical Development and Medical Affairs Exhibit List: Exhibit 24 - Power of Attorney /s/ Johnny John 2022-04-05 EX-24 2 attachment1.htm EX-24 DOCUMENT

                         LIMITED POWER OF ATTORNEY FOR
                        SECTION 16 REPORTING OBLIGATIONS

      Know all by these presents, that the undersigned hereby constitutes and
appoints each of John Purpura and Gerard Michel, acting alone and with full
power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1)   prepare, execute in the undersigned's name and on the undersigned's
      behalf, and submit to the U.S. Securities and Exchange Commission (the
      "SEC") a Form ID, including amendments thereto, and any other documents
      necessary or appropriate to obtain codes and passwords enabling the
      undersigned to make electronic filings with the SEC of reports required by
      Section 16(a) of the Securities Exchange Act of 1934 or any rule or
      regulation of the SEC;

(2)   execute for and on behalf of the undersigned, in the undersigned's
      capacity as an officer of Delcath Systems, Inc. (the "Company"), Forms 3,
      4, and 5 in accordance with Section 16(a) of the Securities Exchange Act
      of 1934 and the rules thereunder, and any other forms or reports the
      undersigned may be required to file in connection with the undersigned's
      ownership, acquisition, or disposition of securities of the Company;

(3)   do and perform any and all acts for and on behalf of the undersigned which
      may be necessary or desirable to complete and execute any such Form 3, 4,
      or 5, or other form or report, and timely file such form or report with
      the SEC and any stock exchange or similar authority; and

(4)   take any other action of any type whatsoever in connection with the
      foregoing which, in the opinion of such attorney-in-fact, may be of
      benefit to, in the best interest of, or legally required by, the
      undersigned, it being understood that the documents executed by such
      attorney-in-fact on behalf of the undersigned pursuant to this Power of
      Attorney shall be in such form and shall contain such terms and conditions
      as such attorney-in-fact may approve in such attorney-in-fact's
      discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of April 5, 2022.

                                               /s/ Johnny John
                                               ---------------------
                                               Johnny John